Patents by Inventor Mark Uden

Mark Uden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11667887
    Abstract: The present invention relates to a method of producing a recombinant protein in a host cell comprising adding Polyethyleneimine (PEI) during cell culture. Addition of PEI to the cell culture as a fermentation enhancer can result in reducing the viscosity of the cell culture, and/or increasing the extracellular concentration of the recombinant protein, and/or reducing the duration of cell culture to the point of harvest or protein recovery.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 6, 2023
    Assignee: Glaxo Group Limited
    Inventors: Gary Brian Finka, Michael Hoare, Mark Uden, Ioannis Voulgaris
  • Patent number: 11566347
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 31, 2023
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Valeriu Damian, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Publication number: 20230028110
    Abstract: The present invention provides high-affinity anti-TCR delta variable 1 (anti-V?1) antibodies and antibody fragments thereof. The present invention also provides compositions and pharmaceutical compositions comprising such antibodies, and method of making such antibodies. The present invention also provides methods of treatment and medical uses involving the antibodies.
    Type: Application
    Filed: February 17, 2022
    Publication date: January 26, 2023
    Applicant: Adaptate Biotherapeutics Ltd.
    Inventors: Mihriban TUNA, Oxana POLYAKOVA, Mark UDEN, Robert GOOD, Joshua FREEDMAN, Shefali BHUMBRA, Natalie MOUNT, Aoife MCGINLEY, Dan FOXLER
  • Publication number: 20220403025
    Abstract: The invention relates to anti-V?1 antibodies or fragments thereof for use in methods of treating a cancer, an infectious disease or an inflammatory disease in a subject in need thereof.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 22, 2022
    Inventors: Natalie Mount, Oxana Polyakova, Robert Good, Mark Uden, Raj Jaysukhlal Mehta, Oliver NUSSBAUMER
  • Patent number: 11254753
    Abstract: The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also relates to compositions comprising said variant IgG4 antibodies.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: February 22, 2022
    Inventors: Hella Bosteels, Shugui Chen, Kayeleigh Farrow, Richard Kucia-Tran, William John Kenneth Lewis, Andrew S. Thomson, Mark Uden
  • Publication number: 20220010276
    Abstract: The present invention relates to a method for the isolation of lymphocytes (in particular ?? T cells) from a non-haematopoietic tissue sample comprising the steps of culturing a non-haematopoietic tissue sample which is an intact biopsy obtained from a non-haematopoietic tissue in the presence of Interleukin-2 (IL-2) and Interleukin-15 (IL-15); and collecting a population of lymphocytes cultured from the non-haematopoietic tissue sample. Methods of subsequent expansion are provided, as well as populations of isolated cells obtained by the method and uses thereof.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 13, 2022
    Inventors: Shristi BHANDARI, Samuel FLORENCE, Andrew HUTTON, Louisa MATHIAS, Oliver NUSSBAUMER, Kalle SODERSTROM, Mark UDEN
  • Publication number: 20220010277
    Abstract: The invention relates to a method for the isolation of lymphocytes (in particular ?? T cells) from a non-haematopoietic tissue sample comprising the steps of: culturing the non-haematopoietic tissue sample in the presence of (a) Interleukin-2 (IL-2) or Interleukin-9 (IL-9); (b) Interleukin-5 (IL-15); and (c) Interleukin-21 (IL-21); and collecting a population of lymphocytes cultured from the non-haematopoietic tissue sample. Methods of subsequent expansion are provided, as well as populations of isolated cells obtained by the method and uses thereof.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 13, 2022
    Inventors: Shristi BHANDARI, Samuel FLORENCE, Andrew HUTTON, Louisa MATHIAS, Oliver NUSSBAUMER, Kalle SODERSTROM, Mark UDEN
  • Patent number: 11203632
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: December 21, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Valeriu Damian, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Patent number: 11098312
    Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 24, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Robyn Alexandra Emmins, Gary Brian Finka, Michael Hoare, Alan Peter Lewis, William John Kenneth Lewis, Adam Daniel McInally, Mark Uden, Ioannis Voulgaris
  • Publication number: 20200339663
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Application
    Filed: May 12, 2020
    Publication date: October 29, 2020
    Inventors: Valeriu DAMIAN, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Patent number: 10633673
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 28, 2020
    Assignee: GLAXO GROUP LIMITED
    Inventors: Mark Uden, Ekaterini Kotsopoulou
  • Publication number: 20190225708
    Abstract: The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also relates to compositions comprising said variant IgG4 antibodies.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 25, 2019
    Inventors: Hella BOSTEELS, Shugui CHEN, Kayeleigh FARROW, Richard KUCIA-TRAN, William John Kenneth LEWIS, Andrew S. THOMSON, Mark UDEN
  • Publication number: 20190177734
    Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.
    Type: Application
    Filed: May 4, 2017
    Publication date: June 13, 2019
    Inventors: Robyn Alexandra EMMINS, Gary Brian FINKA, Michael HOARE, Alan Peter LEWIS, William John Kenneth LEWIS, Adam Daniel McINALLY, Mark UDEN, Ioannis VOULGARIS
  • Publication number: 20180222964
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Inventors: Valeriu DAMIAN, Austin Keith DOYLE, Laura Maria HALO, Emma R. HARDING, Xuan HONG, Alan Peter LEWIS, Mark UDEN
  • Publication number: 20180135008
    Abstract: The present invention relates to a method of producing a recombinant protein in a host cell comprising adding Polyethyleneimine (PEI) during cell culture. Addition of PEI to the cell culture as a fermentation enhancer can result in reducing the viscosity of the cell culture, and/or increasing the extracellular concentration of the recombinant protein, and/or reducing the duration of cell culture to the point of harvest or protein recovery.
    Type: Application
    Filed: May 13, 2016
    Publication date: May 17, 2018
    Inventors: Gary Brian FINKA, Michael HOARE, Mark UDEN, Ioannis VOULGARIS
  • Patent number: 9534246
    Abstract: The invention provides methods for the rapid identification and selection of cell lines suitable for biopharmaceuticals production, which do no utilize animal derived components.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: January 3, 2017
    Assignee: Glaxo Group Limited
    Inventors: Ekaterini Kotsopoulou, Richard Priest, Mark Uden
  • Publication number: 20160010111
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Application
    Filed: September 30, 2015
    Publication date: January 14, 2016
    Inventors: Mark UDEN, Ekaterini Kotsopoulou
  • Patent number: 9163249
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: October 20, 2015
    Assignee: Glaxo Group Limited
    Inventors: Mark Uden, Ekaterini Kotsopoulou
  • Publication number: 20130310281
    Abstract: The present invention provides novel antigen-binding proteins derived from human germline VH domains, having improved expression and improved biophysical characteristics.
    Type: Application
    Filed: January 27, 2012
    Publication date: November 21, 2013
    Applicant: Glaxo Group Limited
    Inventors: Emma R. Harding, Ekaterini Kotsopoulou, Alan Peter Lewis, Susannah Thornhill, Mark Uden
  • Publication number: 20130090259
    Abstract: The invention provides methods for the rapid identification and selection of cell lines suitable for biopharmaceuticals production, which do no utilize animal derived components.
    Type: Application
    Filed: June 29, 2011
    Publication date: April 11, 2013
    Inventors: Ekaterini Kotsopoulou, Richard C. Priest, Mark Uden